New Childhood Cancer Advocacy Group States Seven Key Aims

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Russ Conroy

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Roman Fabbricatore

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Related Content

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Russ Conroy

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Roman Fabbricatore

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.